Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XIENCE 28 Global Study
NCT03355742Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2018
- Primary completion
- Oct 2019
- Countries
- 13
01
Overview
Open-label, single-arm trial, sponsored by Abbott Laboratories. Primary endpoint: Net Adverse Clinical Endpoint. Started Feb 2018; status: completed.
Beyond the preview
Go deeper on NCT03355742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355742.